IFNB1 and myeloid sarcoma: The expression of dopamine receptor 5 (DAR5) in the peripheral blood mononuclear cells (PBMCs) is decreased in MS patients but progressively upregulated when treated with IFN-β [11, 12], though its exact role in the disease is not clear.